Work

Cost-effectiveness analysis of mosunetuzumab compared with novel alternative immunotherapies in patients with third-line or later relapsed/refractory follicular lymphoma in Japan

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-6178

Authors: Ritsuro Suzuki, Hiroyuki Sakamaki, Naoki Inubashiri, Misako Makishima, Haruna Aoki, Eiki Yoshida, Hikaru Inoue, Atsuko Kawasaki, Hidetoshi Shibahara, Tatsunori Murata, Shigeo Fuji

Institutions: Shimane University, Chugai Pharmaceutical Co., Ltd. (Japan), Crecon Medical Assessment Inc. (Japan), Osaka International Cancer Institute

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417016235

Cites:

Cited by:

Related to: